# A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

> **NCT07216482** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 975 (estimated)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Enlicitide
- **DRUG:** Rosuvastatin
- **DRUG:** Placebo for Enlicitide
- **DRUG:** Placebo for Rosuvastatin

## Key facts

- **NCT ID:** NCT07216482
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-11
- **Primary completion:** 2026-12-02
- **Final completion:** 2027-03-01
- **Target enrollment:** 975 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07216482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07216482, "A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT07216482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*